As of Aug 28
| +0.11 / +2.17%|
The 3 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 4.00. The median estimate represents a +131.66% increase from the last price of 5.18.
The current consensus among 3 polled investment analysts is to Buy stock in Corcept Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.